Dual-Mechanism Drop Wins FDA Approval - Scorecard - MDSpire

Dual-Mechanism Drop Wins FDA Approval

FDA approves Tenpoint Therapeutics’ YUVEZZI eye drop for presbyopia

  • February 2, 2026

  • 2 min

Share

Clinical Scorecard: Dual-Mechanism Drop Wins FDA Approval

At a Glance

CategoryDetail
ConditionPresbyopia
Key MechanismsCombination of carbachol (cholinergic agent) and brimonidine tartrate (alpha-adrenergic agonist) to induce pupil constriction and improve near visual acuity.
Target PopulationAdults experiencing presbyopia, typically emerging in mid-40s.
Care SettingOphthalmology clinics and primary care settings.

Key Highlights

  • First dual-agent eye drop approved for presbyopia treatment.
  • Demonstrated superiority over individual components in clinical trials.
  • Achieved significant improvements in near visual acuity for up to eight hours.
  • No serious treatment-related adverse events reported.
  • Low rates of ocular hyperemia compared to carbachol alone.

Guideline-Based Recommendations

Diagnosis

  • Assess near vision decline in adults, typically starting in mid-40s.

Management

  • Consider YUVEZZI as a pharmacologic option for presbyopia management.

Monitoring & Follow-up

  • Monitor for common adverse events such as headache and ocular irritation.

Risks

  • Potential for temporary ocular irritation and impaired vision.

Patient & Prescribing Data

Adults with presbyopia seeking non-invasive treatment options.

Once-daily dosing may enhance patient adherence and satisfaction.

Clinical Best Practices

  • Educate patients on the dual-mechanism of YUVEZZI and its benefits.
  • Monitor patients for adverse effects during follow-up visits.
  • Encourage patients to report any changes in vision or discomfort.

References

Original Source(s)

Dual-Mechanism Drop Wins FDA Approval

  • February 2, 2026

Related Content

The Growth Potential of Refractive Surgery for Myopia

Capitalizing on the growth potential of refractive surgery hinges on embracing an array of procedures, challenging conventional mindsets and prioritizing patient-centered care.

The Evolution of Treatments for Emmetropic Presbyopia

Often, these patients are unhappy with this reality check of aging and do not want to wear reading glasses, which is why practitioners and industry are always looking for ways to help. The challenge is to develop therapies that correct presbyopia while maintaining the emmetrope’s clear distance vision.

PC-IOL Bulletin

Presbyopia-correcting intraocular lenses deliver a substantial lifestyle improvement, so offering them is becoming the new standard of care among cataract surgeons.